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I Study rationale and methods
In recent years signals from both formal and informal 
monitoring sources based in a number of countries have 
been flagging critical new developments within Europe’s 
MDMA/ecstasy market. These include signs of increased 
MDMA production and availability, the opening of new 
online markets, reports of increased use, the issuing of 
alerts on both high-dose MDMA tablets and adulterated 
tablets, and evidence of low but potentially rising numbers 
of MDMA-related hospital admissions, and even deaths in 
some countries.
In order to investigate these changes and developments in 
the supply and demand of one of Europe’s more 
established illicit drugs, a targeted ‘trendspotter’ study 
was initiated by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and carried out between 
August and October 2015. The primary aim of the study 
was to increase understanding of recent changes in the 
MDMA market in Europe. More specifically, the study set 
out to explore: levels and patterns of MDMA use; the 
MDMA market including production, supply and product 
availability; MDMA-related harms and deaths; and 
implications for law enforcement, health and social 
responses.
The study commenced with a phase of data collection and 
a literature review undertaken by a team drawn together 
from different sectors within the EMCDDA, and culminated 
in an expert meeting in Lisbon on 22–23 October 2015. 
Fourteen experts attended the meeting, sharing their 
experiences and contributing to an in-depth analysis of the 
topic, providing insights from drug research and 
monitoring, wastewater analysis, law enforcement and 
health perspectives. 
The trendspotter study methodology incorporates a range 
of different investigative approaches and data collection 
from multiple sources. This study included two expert web 
surveys, a review of the international literature and 
available monitoring data, 15 expert presentations and 
findings from three facilitated working groups. Analysis 
was based on triangulation of these information sources, 
with a view to providing as complete and verified a picture 
as possible. The combination of routine and survey data 
with key informant reports and law enforcement 
intelligence provided a rich and in-depth view of a rapidly 
changing phenomenon. This report summarises the study 
findings and conclusions. Where results are literature-
based, references are cited, otherwise findings are based 
on EMCDDA monitoring and the qualitative sources 
described above. 
I A short history of MDMA/ecstasy
The German pharmaceutical company Merck first filed a 
patent for MDMA in 1912 but it was only in 1960 that its 
synthesis was first reported (1). The substance was initially 
intended to be used as an anti-clotting agent and 
underwent animal testing. It was not until the 1970s, 
however, that the psycho-pharmacologist Alexander 
Shulgin began exploring the use of the drug in humans and 
the substance was taken up in certain American 
psychotherapy circles. The 1980s saw the beginning of the 
open sale and recreational use of MDMA, first known as 
‘empathy’ and shortly after as ‘ecstasy’. Its rise was closely 
associated with the popular house/rave and techno music 
scenes that started in Chicago and quickly spread through 
Europe, and with the so-called Second Summer of Love in 
the United Kingdom in 1988. In terms of control, MDMA 
was placed on Schedule I of the United Nations 
Convention on Psychotropic Substances, 1971 in 1986. 
In part as a response to a number of high-profile MDMA-
related deaths, the 1990s saw an increase in the 
development of harm reduction initiatives including safer 
nightlife programmes and pill testing projects. While in the 
early 2000s there was a renewed popularity and 
mainstreaming of the electronic dance music scene, the 
end of the decade was characterised by a shortage of 
quality MDMA products on the market due to the limited 
availability of precursors. During this period many ecstasy 
tablets on the illicit market contained little or no MDMA, 
with its replacement by piperazines, cathinones and other 
new psychoactive substances (NPS). From 2010 onward 
the tide appeared to turn again, and the new developments 
in the MDMA market in 2011–15 are the focus of the rest of 
this report. 
I A range of MDMA products
The ‘ecstasy-type’ drugs MDMA, MDA and MDEA belong to 
the group of synthetic compounds collectively known as 
amphetamine-type stimulants. MDMA 
(3,4-methylenedioxyamphetamine) is a member of the 
substituted phenethylamine class of drugs. MDMA was the 
original chemical in pills sold as ecstasy, along with 
adulterants such as caffeine. In the last decade, however, 
many other substances — both active drugs(s) and 
adulterants — have been identified in so-called 
ecstasy pills. 
(1)  Narconon Drug Rehabilitation and Education (2015), ‘Drug information: 
history of ecstasy (MDMA)’ (www.narconon.org/drug-information/
ecstasy-history.html).
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MDMA freebase is a thick oil that is unstable and highly 
caustic and therefore not suitable for consumption. The 
synthesis of MDMA involves the conversion of the oil into a 
crystallised salt, the most common being a hydrochloride, 
although phosphate salt is also found. 
The MDMA products that are consumed include crystal 
MDMA, which is also available as a powder, and MDMA in 
tablet form. Pure crystal MDMA is translucent white with a 
coarse structure and the crystals may be pulverised into 
powder with a ‘crystalline’ shimmer. Crystals and powders 
may be sold loose (in bags or papers/parachutes) or in 
capsules. Tablets are usually pressed from powders, but 
occasionally may contain discernible crystals. It is unclear 
whether this is linked to poor grinding methods or is a 
marketing technique.
I  MDMA markets — production and supply
I Global market context
At the global level the precursor trade, production and 
trafficking of MDMA has in recent decades been operated 
by organised crime groups (OCGs) based in north-west 
Europe, and MDMA precursors such as safrole 
(3,4methylenedioxyallybenzene, a liquid extracted from 
sassafras plants) and later PMK (piperonyl methyl ketone, 
itself derived from safrole) were imported from Asia. Until 
recently, facilities in the Netherlands and Belgium have 
represented the only major MDMA production hub, with 
products trafficked by crime groups primarily to European 
and North American markets. Although production in the 
Netherlands and Belgium is on the increase, with 
clandestine laboratories becoming larger and more 
professional, north-west Europe is no longer the sole 
source of MDMA on the global market (UNODC, 2015). In 
recent years production has reportedly been taking place 
in other countries, including both Canada and China.
North America is seeing increases in MDMA trafficking and 
use, with production sites found both in the United States 
and Canada. MDMA is also gaining popularity in South 
America, with Brazil already having a major market 
(UNODC, 2015), and with recent law enforcement reports 
suggesting that MDMA has been exchanged for cocaine in 
Brazil by European OCGs. In addition, east and south-east 
Asia and Oceania now also represent major ecstasy 
markets (UNODC, 2015).
Reports suggest that high-strength European tablets are 
favoured by consumers in Asia. According to one 
hypothesis, the increased availability of high-purity MDMA 
tablets on the global market reflects the growing 
importance of the Asian market in global MDMA trade. In 
North America these stronger tablets are often referred to 
as ‘Euros’.
I MDMA precursor trends
The four main MDMA precursors are safrole 
(3,4-methylenedioxyallybenzene (2)), isosafrole 
(3,4methylenedioxypropenylbenzene (3)), piperonal 
(3,4methylenedioxybenzaldehyde (4)) and PMK (piperonyl 
methyl ketone, also known as 3,4methylenedioxyphenyl-2-
propanone or 3,4MDP2P (5)). Trade in these four 
substances is internationally controlled. While licit trade in 
PMK is virtually non-existent, licit trade in (iso)safrole/
safrole-rich oils amounts to approximately 4 500 litres per 
annum, and legitimate trade of piperonal reached almost 
2 400 tonnes in 2013 (INCB, 2014). Most illicit MDMA is 
now produced with PMK as the starting material. PMK has 
typically been produced in China and trafficked into 
Europe via the ports of Rotterdam and Antwerp for illicit 
MDMA production (UNODC, 2012). 
The shortage of safrole in 2008 and the following years 
was associated with several new substances appearing on 
the MDMA precursor market. In China a new MDMA 
pre-precursor called PMK-glycidate became available 
around 2010, revitalising MDMA production in recent 
years. PMK-glycidate is not derived from safrole and is 
therefore not vulnerable to natural shortages. To date, the 
trade in PMK-glycidate remains legal, which makes it 
difficult for law enforcement to control. With PMK-
glycidate, new ports in countries that are not traditionally 
associated with MDMA production are reported to be 
increasingly used as entry points, with seizures reported in 
Romania, Slovenia and Spain.
Seizures of PMK-glycidate amounting to 2 077 kg were 
reported in 2013, and in June 2014 one tonne of PMK-
glycidate (enough to make seven million ecstasy tablets, 
according to the police) was found in Barcelona’s port on a 
shipment from Shanghai bound for Maastricht in Holland 
(Daly, 2015). In addition, reports from law enforcement 
indicate 4metoxyBMK is sometimes sold to unsuspecting 
MDMA producers, who then produce PMMA instead of 
MDMA.
(2) IUPAC name: 5-(2-propenyl)-1,3-benzodioxole.
(3) IUPAC name: 5-(Prop-1-enyl)benzo[d][1,3]dioxole.
(4) IUPAC name: 1,3-Benzodioxole-5-carbaldehyde.
(5) IUPAC name: 3,4-methylenedioxyphenylpropan-2-one.
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I Production and trafficking
Production of MDMA takes place mainly in the Netherlands 
and Belgium, and the predominant synthesis technique 
used is reductive deamination. Chemicals essential to the 
process, such as acetone or methylamine, have reportedly 
been bought from countries that are not traditionally 
associated with MDMA production, for example Germany, 
Poland or Romania. 
There are currently a small number of OCGs involved, and it 
is common for production facilities to specialise in one 
production step, such as pre-precursor conversion, MDMA 
oil synthesis, crystallisation or tableting. Although all these 
steps are routinely performed in the Netherlands and 
Belgium, tableting also occurs in other countries, such as 
the Czech Republic, Germany and Spain. This 
compartmentalisation of the production process appears 
to be aimed at reducing vulnerability to law enforcement 
threats. Other new developments include the use of mobile 
production sites on trucks, which helps to extend the 
geographical span of production. There is also evidence of 
‘production to order’, with MDMA laboratories closing down 
once a production run is completed. The lack of excess 
precursors seized during raids on illicit production sites 
suggests that the correct volumes of precursors are 
provided ‘on demand’ for each production batch.
A number of new developments appear to be playing a role 
in the recent increased production of high-quality MDMA. 
These include reports of more sophisticated and industrial-
scale MDMA labs and increasing production expertise 
(especially in the Netherlands and Belgium). Production 
volumes have also been rising, and in some MDMA 
production sites custom-built reaction vessels have been 
found with a capacity of 750 litres. Dutch labs appear to 
be producing higher purity products than elsewhere, which 
may be linked to the skills of the illicit chemists (cooks). 
Producers also have easy access to cheap tableting 
machinery from China, and to pre-mixed coloured 
excipients and tablet stamps. The issue of low-level but 
increasing local production of MDMA tablets has also been 
identified. There are reports of ‘hobby chemists’ from a 
number of countries, and also individuals who purchase 
MDMA crystals from internet markets and produce tablets 
themselves. 
Wastewater analysis can provide useful indicators of signs 
of MDMA production; for example, some cities in the 
Netherlands exhibited abnormally high values for MDMA, 
which was due to the release of MDMA directly into the 
sewer system, presumably to avoid law enforcement 
activities (EMCDDA, 2015b). In addition, an increase in the 
dumping of dangerous waste products from MDMA 
production processes has been reported by law 
enforcement agencies and is considered an environmental 
concern in the Netherlands and Belgium.
With regard to trafficking, the vast majority of European 
production is destined for internal markets, with Germany 
and the United Kingdom being the most common 
destinations. There is no evidence of MDMA being imported 
into the European Union (EU). Assessing recent trends in 
MDMA seizures is difficult due to the absence of data from 
some countries that are likely to make important 
contributions to this total. The Netherlands reported seizing 
2.4 million MDMA tablets in 2012, and if a similar figure may 
be assumed for 2014 it can be estimated that around 
5.5 million MDMA tablets were seized in the EU in that year. 
This would be more than double the number seized in 2009. 
Organised crime groups also produce MDMA for 
intercontinental export (to Australia, Brazil and the United 
States in particular). It is reported that some MDMA is 
being exported through the Balkan Route, and Turkey has 
recently started seizing large amounts of MDMA 
(3.6 million tablets in 2014). It remains unclear how much 
MDMA eventually leaves the country, and to which 
countries it is being trafficked. Export may be a particularly 
lucrative option, with prices often much higher in non-EU 
countries. MDMA is trafficked by road, rail, sea and air. 
Postal packages are also becoming popular as internet 
sales are increasing. A new development is the trade in 
MDMA oil, for subsequent conversion, which is trafficked 
between criminal organisations within the Netherlands, 
within the EU (e.g. to Spain), and for export (e.g. to 
Australia or Brazil). The oil can be re-crystallised on arrival 
at its destination. Seizures of MDMA alongside other 
products suggest that it is tied in to broader multi-
commodity trafficking processes.
I MDMA trade in online drug markets
MDMA is one of the most popular drugs bought through 
online and anonymised darknet markets. These markets 
exist on the deep web, an area of the internet that has 
been intentionally hidden and is inaccessible through 
standard web browsers. Based on an analysis of 16 
darknet drug marketplaces between 2013–15, Soska and 
Christin estimated that MDMA accounted for about 25 % 
of market demand (Soska and Christin, 2015). Similarly, 
Ciancaglini et al. of TrendLabs conclude in their 2015 
report Below the surface: Exploring the deep web that 
MDMA is the third most commonly sold drug on darknet 
sites (after cannabis and pharmaceuticals). The Global 
Drug Survey (Winstock, 2015), an online survey that 
specifically targets drug users, found that MDMA was 
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reported to be the most commonly purchased drug 
through darknet markets among their sample. 
Studies suggest that a large proportion of darknet 
purchases of MDMA may be for resale. MDMA annual 
revenue on the Silk Road marketplace has been estimated 
at just under USD 20 million, with 45 % generated by 
high-price product listings — suggesting transactions at 
the middle to wholesale level (Aldridge and Decary-Hetu, 
2014). In 40 % of the most expensive listings of MDMA, the 
average listing price (mean USD 2 072) and the quantities 
(mean 26 g) were consistent with purchase for resale 
(Aldridge and Decary-Hetu, 2014).
For MDMA, and for other drugs sourced via darknet 
markets, studies have highlighted user reports of higher 
quality products being available than from alternative 
supply sources (Barratt et al., 2014; Winstock, 2015; Van 
Hout and Bingham, 2013a). Purchasing from the darknet 
also enables customers to buy from vendors located in 
countries perceived to be associated with the production 
of high-potency drugs (e.g. the Netherlands) (Van Hout and 
Bingham, 2013b). 
There have also been reports of the sale of MDMA over 
surface websites such as the now-defunct Shiny Flakes 
and via social networking applications. 
I Recent increases in purity
Prior to 2005 most tablets tested in Europe contained 
MDMA or another MDMA-like substance (MDEA, MDA) as 
the only psychoactive ingredient. In France, for example, 
the SINTES monitoring system showed that 82 % of more 
than 7 000 tablets collected and analysed between 1999 
and 2004 contained MDMA. Pills with a dose higher than 
150 mg were very rare (Giraudon and Bello, 2003, 2007). 
Changes occurring in the late 2000s saw the virtual 
disappearance of MDMA as the active ingredient in 
ecstasy tablets, accompanied by increased tablet 
adulteration/substitution with other psychoactive 
substances. The downward trend was most pronounced in 
2009 when seizure data suggest that the majority of 
MDMA tablets on European markets contained no MDMA 
at all.
From 2010/11 MDMA products have gradually re-emerged 
on the market, often at higher levels of purity. The first 
powders that appeared after the MDMA shortage were 
reportedly very pure; however, their quality declined over 
time. The subsequent market development saw the 
growing popularity of MDMA crystals, which were less 
easy to adulterate. Some recently produced batches of 
MDMA tablets contained discernible crystals, apparently 
as a strategy to increase user trust. 
In the 1990s and 2000s the average MDMA content of 
tablets was somewhere between 50–80 mg, as reported 
by drug checking services and forensic institutes (Wood 
et al., 2011). At present the averages are closer to 125 mg 
MDMA per tablet, while there are also ‘super pills’ found on 
the market in some countries with a reported range of 
270–340 mg. There are reports of large variations in the 
dosage in similar looking tablets. Data from the Drug 
Information and Monitoring System (DIMS) in the 
FIGURE 1
DIMS reports of MDMA tablet content levels in the Netherlands, 2003–15
Source: DIMS, 2015.
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Netherlands, which tests around 10 000 drug samples 
annually, confirm both the re-emergence of MDMA in the 
country, starting in 2011–12 then increasing rapidly from 
2013, and the trend of increasing purity of MDMA pills 
(Figure 1). Figure 1 shows that over half (53 %) of all 
ecstasy tablets tested in 2015 contained over 140 mg of 
MDMA compared to just 3 % in 2009.
In addition to increases in MDMA content, there has also 
been an increase in the size of some of the tablets 
available. In France the SINTES monitoring system 
reported that the weight of MDMA pills increased on 
average from 204 mg in 2009 to 325 mg in 2014. 
In March 2014 the EMCDDA and Europol jointly released 
an early warning notification on MDMA tablets with 
dangerously high levels of MDMA found in the 
Netherlands, Belgium, Switzerland and the United 
Kingdom. On 2 October 2015 the Dutch Trimbos Institute 
issued an alert warning about yellowish-white tablets with 
the Amsterdam Dance Event (ADE) logo, in circulation in 
the Netherlands, containing 300 mg per tablet (www.
mixmag.net/read/dutch-health-officials-warn-of-ade-
ecstasy-pills-news). 
I Adulteration/substitution
Unlike powders or crystals, which in theory can be 
absolutely pure, tablets cannot contain solely MDMA, as 
it is impossible to press the salt into pills without the 
addition of binding agents. Typically, MDMA does not 
exceed 30–40 % of the material constituting a tablet, the 
bulk of it being formed by binders/fillers. A filler 
substance with no pharmacological properties is not 
considered an adulterant. Information provided by the 
Spanish drug checking services Energy Control shows 
that caffeine was an adulterant in both tablets and crystal 
samples tested; however, tablets also contained mCCP 
and TFMPP (both piperazines), while crystals were more 
commonly adulterated with procaine and 
methamphetamine.
The euphoric and entactogenic effects of MDMA have 
proven very difficult to replicate in any other substance. 
Numerous NPS have been used as adulterants/substitutes 
in ecstasy tablets, but most seem to produce less 
desirable effects. However, mephedrone emerged 
between 2007 and 2009, and became popular in several 
EU countries during the times of MDMA shortage (Brunt et 
al., 2011). Recently, 4fluoroamphetamine (4FA), has been 
gaining popularity in the Netherlands, where it is known as 
‘ecstasy light’ because of its effects, reportedly ranging 
between those of amphetamine and MDMA (Linsen et al., 
2015). Reports from the Belgian Early Warning System 
identified a number of MDMA tablets containing a range of 
different NPS seized at the Tomorrowland festival, 
including, for example, alpha PVP. In Portugal the 
CHECK!N/APDES drug testing service notes that the 
closure of shops selling NPS in 2013 appeared to coincide 
with the re-emergence of MDMA pills on the country’s drug 
market.
Other substances reported to be found in tablets sold as 
MDMA/ecstasy included 2CB, ketamine, piperazines 
(TMFPP, mCPP, BZP), amphetamine, PMA and PMMA. In 
2009 piperazines were present in most ‘ecstasy’ tablets 
sold in Europe, which probably contributed to the observed 
decrease in popularity of the drug. Another adulterant is 
PMMA, which has proven particularly hazardous.
In recent years, all EMCDDA alerts of adulterants/
substitutes present in MDMA/ecstasy tablets were related 
to PMMA, including 11 alerts of PMMA-associated deaths 
between 2011 and 2015. Recently, an alert of tablets 
containing PMMA was released in June 2015 by 
saferparty.ch in Bern, Switzerland (relating to 81 mg 
PMMA, a pink round tablet with a crown logo). In July 2015 
three deaths associated with tablets containing PMMA 
were reported in Poland (orange triangular tablets with a 
Superman logo).
I Marketing of MDMA
A key feature of the contemporary MDMA market has been 
the creative and sometimes aggressive marketing of 
products, most recently particular MDMA tablet brands. 
This has included the use of logos (e.g. Superman, UPS), a 
variety of shapes, bright and fluorescent colours, and 
larger size/weight tablets. MDMA tablets are also 
produced specifically for individual events, typically music 
festivals such as Tomorrowland or Amsterdam Dance 
Event (see Figure 2). The Dutch police report a sharp 
increase in the number of new tablet designs, from 50 new 
designs identified in 2012 to a peak of 174 in 2014. This 
product specialisation and differentiation has had its own 
micro trends. Often a new brand of high-quality MDMA 
tablets comes out on the market associated with a 
particular Dutch producer. These gain a reputation among 
customers but are rapidly copied by other producers and 
lower potency versions of the same product are released 
onto the market. 
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FIGURE 2
MDMA tablets designed for specific events
Tablet made for the Tomorrowland electronic music festival (Belgium). This 
tablet was analysed in Switzerland in 2015 and found to contain a 
dangerously high level of MDMA (more than 200 mg).
Photo © Pharmaceutical Control Laboratory, Office of the Cantonal 
Pharmacist, Bern, Switzerland
Tablet made for the Amsterdam Dance Event (ADE) electronic music 
festival, also found to contain dangerously high levels of MDMA (2015).
Photo © DIMS, Trimbos Institute, the Netherlands
I MDMA use and cultural context
I Levels and patterns of MDMA use
While tablets known as ecstasy were for decades the main 
form of marketed MDMA, there was a discernible shift 
around ten years ago as users lost trust in tablets and 
began to switch to using MDMA powders and crystals. 
Since 2010 tablets have had a better reputation for quality, 
and on the contemporary European market MDMA crystal/
powder and tablets can be parallel and sometimes 
competing products. Among users, the preference for 
particular product types varies by country and appears to 
be associated with availability and driven largely by a 
search for quality/potency. Crystal MDMA may be regarded 
by users as more difficult to adulterate and therefore likely 
to be purer than powders or tablets (this is not always true 
in reality). Results from the recent online Global Drugs 
Survey support this mixed pattern of use of both MDMA 
pills and powders, and differing product preferences by 
country (Winstock, 2015). Similarly, patterns and levels of 
use are also interlinked with local and national stimulant 
markets and the availability and quality of alternative 
products, for example with methamphetamine in the Czech 
Republic and cocaine in Spain.
Much information on MDMA use comes from general 
population and targeted surveys, and most European 
surveys have historically collected data on ecstasy rather 
than MDMA use. The most recent EU-level estimate 
suggests that around 1.8 million young adults (aged 
15–34) used MDMA/ecstasy in the last year (1.4 % of this 
age group), with national estimates ranging from 0.3 % to 
5.6 %. Countries with the highest prevalence of MDMA use 
in Europe include the Netherlands, the Czech Republic, the 
United Kingdom, Bulgaria and France. MDMA is the 
predominant stimulant used (ahead of cocaine and 
amphetamines) in a number of countries in this young 
adult group, although the prevalence may be low (see 
Figure 3). Wastewater data from the SCORE group found 
the highest MDMA concentrations in cities in the 
Netherlands and Belgium and the lowest concentrations in 
southern European cities (EMCDDA, 2015b). 
FIGURE 3
Predominant stimulant used by country, according to last 
year prevalence of use for young adults (aged 15–34)
Cocaine
Amphetamines
Ecstasy
None
No data available
Source: EMCDDA Statistical Bulletin, available at http://www.emcdda.
europa.eu/data/stats2015
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MDMA is often taken alongside other substances, in 
particular alcohol. This study identified reports of small-
scale and sometimes niche polydrug combinations 
including: MDMA and amphetamine; MDMA, amphetamine 
and ketamine (triphasic); and MDMA and LSD (known as 
‘candyflipping’).
Trends in MDMA use tend to mirror the availability and 
supply of the drug, with increases in Europe during the 
1990s and decreasing prevalence levels in the early 
2000s, especially among those countries with higher 
levels of use. Among the 12 countries that have produced 
new surveys since 2013, results suggest a recent overall 
increase in Europe, with three-quarters (nine) reporting 
higher estimates than in the previous comparable survey. 
It seems likely that there is something of a ripple effect, 
with certain trendsetter countries such as the Netherlands 
and the United Kingdom reporting increases in prevalence 
that have possibly already plateaued, with another set of 
countries following the same trend a year or two later. At 
the other end of the scale, Latvia and Lithuania, for 
example, have not reported any increase in MDMA use nor 
in the availability of high-purity tablets. Where city-level 
information is available this appears to confirm an overall 
rising trend. A German city monitor based in Frankfurt 
(MoSyD) identified a significant increase in MDMA 
prevalence in a school survey of 15- to 18-year-old 
students, with the prevalence rate doubling from 2 % to 
4 % between 2013 and 2014 (Werse and Kamphausen, 
2015). Similarly, a local monitor in Bergen, Norway (Fore 
Var) reported strong increases in MDMA use and 
availability between spring 2014 and autumn 2015 
(Flesland and Knoff, 2015).
Wastewater data also provide some insight on trends, with 
a sub-set of cities involved in multiple wastewater 
monitoring campaigns between 2011–15. Strong 
increases in MDMA loads were found in cities in the 
Netherlands. 
I MDMA use by clubbers
Typically, surveys of young people who regularly attend 
nightlife events indicate higher levels of drug use 
compared with the general population. This is particularly 
the case for MDMA, which has historically been closely 
linked with nightlife settings and especially electronic 
dance music. The Global Drug Survey reported levels of 
last year prevalence of MDMA use nearly 25 times higher 
(37 %) than that found among the same age group in the 
general population of the EU (GPS 1.5 %) (EMCDDA, 
2015a). This varies greatly by country — see Figure 4.
A study by Boys et al. (2001) identified that the most 
popular reasons for using MDMA were similar to those for 
amphetamines: to ‘keep going’ (91 %), to enhance activity 
(80 %), to feel elated/euphoric (78 %), to stay awake 
(72 %) and to become intoxicated (68 %). The recreational 
use pattern is supported by findings from the SCORE 
wastewater study, with most cities reporting higher loads 
of MDMA detected during the weekend (Friday to Monday) 
than during weekdays (EMCDDA, 2015b). 
FIGURE 4
Recent MDMA use among young adults from different samples: general population surveys (GPS) and Global Drug 
Survey (GDS) (clubbers and non-clubbers)
Source: EMCDDA Statistical Bulletin, available at http://www.emcdda.europa.eu/data/stats2015 and 2014 Global Drug Survey (http://www.globaldrugsurvey.com/)
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I MDMA and electronic dance music 
Electronic dance music (EDM) and the settings where this 
genre is played (clubs, raves or festivals) have historically 
been associated with MDMA consumption. From the late 
1990s to around 2010 this music genre remained mostly 
confined to a limited number of dedicated electronic dance 
festivals across Europe and favoured by a sub-population 
of party-goers. Towards the end of this period club-goers 
began to lose interest in MDMA tablets, which became 
known for their low quality, and began to use powder and 
crystal forms of MDMA, which were considered to have 
higher potency. 
From 2010 onwards the electronic dance music genre 
moved from the margins to the social and cultural 
mainstream, mainly due to large entertainment 
corporations investing in the promotion of EDM acts and 
establishing dedicated events that attract hundreds of 
thousands of party-goers. EDM as an industry sector is 
valued at seven billion dollars yearly (Watson, 2015), and in 
July 2014 Belgium hosted the largest EDM festival with 
almost 360 000 people attending over two weekends. This 
global commercial success of EDM provides a huge and 
fertile ground for the distribution of MDMA among a new 
generation of young consumers who were born after the 
1990s clubbing and ‘ecstasy’ events. The historical link 
between ‘ecstasy’ and the clubbing movement of the 
1990s/2000s has thus been replaced by mainstream EDM 
and ‘MDMA’. Current indications suggest that in higher 
prevalence countries the use of MDMA is no longer a niche 
or subcultural drug (i.e. it is not limited to techno clubs and 
parties); it is now regularly used by a broader group of 
young people in mainstream nightlife settings, bars, 
festivals and house parties. 
The potential consumer base for MDMA is considerable, and 
reports from outreach agencies and ethnographers involved 
in this study suggest that in some countries there is a new 
young generation of MDMA users who do not recognise the 
1990s name of ‘ecstasy’ but know the drug as either MDMA 
or one of a number of street names including ‘Molly’, ‘Adam’, 
‘Mandy’ or ‘Crystal’. Amongst this group of new younger 
users there is in some cases misunderstanding and 
restricted knowledge about MDMA’s effects, composition 
and harms. Often, brands or logos are perceived as 
sufficient indicators of quality and some report that crystal 
and tablets are thought to be different drugs. 
With regard to the impact on drug treatment, MDMA 
problems are rarely reported as a reason for entering 
specialised drug treatment services, with the drug being 
responsible for less than 1 % (around 800 cases) of 
reported first-time treatment entrants in Europe in 2014. 
Just three countries account for over half (56 %) of all 
first-time entrants for MDMA: the United Kingdom (200 
cases), Spain (167 cases) and Turkey (74 cases).
I MDMA harms and deaths
I MDMA-related harms
Reports of health problems related to the use of MDMA 
appear to be relatively uncommon, although there are 
limited systematic data to be able to substantiate this. It is 
likely that the risks are greater when MDMA use is 
associated with polysubstance use and with the use of 
high-purity tablets; there are also increasing reports of 
acute toxicity associated with the use of tablets 
adulterated with other substances such as PMMA. 
Although much more is known about MDMA than other 
club drugs, the evidence is still limited with regard to its 
acute and chronic harms. Much of the clinical evidence is 
derived from case reports, a small number of prospective 
observational studies, retrospective audits and analysis of 
patient records (Abdulrahim and Bowden-Jones, 2015).
Nevertheless, MDMA may potentially cause significant 
acute toxicity, which can manifest as neuropsychiatric 
effects and sympathomimetic/stimulant effects. Common 
effects include agitation, nausea, headache, sweating, 
bruxism, insomnia, blurred vision, increased heart rate and 
raised blood pressure. Severe acute toxicity may be 
characterised by hyperthermia and related secondary 
manifestations; serotonin syndrome; seizures; arrhythmias; 
and, rarely, hyponatremia (Dargan and Wood, 2013). 
MDMA dependence or tolerance is not common. However, 
long-term somatic effects may include damage to the 
central nervous system. Long-term neurological or 
cognitive harms may include impairment of memory, 
impairment of higher cognitive brain functions, and 
damage to dopamine and serotonin nerve terminals; 
although the data to support these associations are 
contradictory. Mental health risks associated with MDMA 
include acute psychosis, confusion, depressed mood 
(‘midweek blues’) and, in the long term, impulsivity, 
depressive symptoms, elevated anxiety and prolonged 
psychosis (Karlsen et al., 2007; Rogers et al., 2009).
I MDMA hospital emergency presentations 
As noted above, there are limited systematic data on acute 
drug toxicity in Europe, and this also applies to MDMA 
12
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(Heyerdahl et al., 2014). Information about acute health 
harms related to MDMA use comes from reports from 
emergency settings. Since 2013 the Euro-DEN network 
has been collecting systematic data on drug-related 
presentations to the emergency departments of 16 
sentinel centres in 10 European countries. From October 
2013 to December 2014 there were 549 presentations 
(8.1 % of the total) that involved acute toxicity relating to 
MDMA use (MDMA was involved in more than 10 % of 
presentations to five of the 16 Euro-DEN centres). A total of 
70.5 % of these presenting were male and the mean age 
was 24.7 years. The mean ± SD number of drugs used in 
the presentations involving MDMA was 1.9 ± 0.7 — around 
half (47.2 %) involved MDMA alone, and just under a third 
(29 %) involved the use of one additional substance, 
usually alcohol. 
The most common clinical features were agitation/
aggression (31.7 %), anxiety (23.9 %), palpitations (12.6 %) 
and chest pain (10.0 %) (Figure 5). Around three-quarters 
of cases were discharged direct from the emergency 
department, most within 12 hours. Some 5 % required 
critical care admission. Sixteen patients developed 
hyperthermia, and significant complications such as 
rhabdomyolysis were more common in these cases, 
including the two deaths seen in this cohort. In terms of 
change over time, there was no significant difference in the 
proportion of presentations involving MDMA between 
October–December 2013 (9.1 %) and October–December 
2014 (7.2 %). 
Reported clinical data from a study in Ibizan emergency 
services situated close to party settings (2008–14) 
identified 8 781 drug-related presentations with around 
half (46 %) involving MDMA. Alcohol and MDMA were the 
most common drug combination among all presentations. 
I MDMA-related deaths
During 2015 case reports of deaths where highly dosed 
MDMA pills may have been involved received much media 
attention in Europe, in particular in France, Belgium, the 
Netherlands and the United Kingdom. 
At a European level, however, the number of MDMA-related 
deaths reported is low, when seen from the perspective of 
the more than 6 000 drug-related deaths that are reported 
annually, most of which relate to opioids (EMCDDA, 2015a, 
2015c). For example, where data on post-mortem 
toxicology were available, there were 14 deaths with 
MDMA reported in Ireland (of 219 cases in total in 2014) 
and five in France (of a total 264 cases in 2013). 
Preliminary analysis of the data reported by countries up to 
October 2015 suggested an increase in some countries 
— for example in Germany, France and Ireland. However, 
as the number of fatalities is small in these countries, no 
significant trend is confirmed so far.
The trend in Turkey is an exception, with 113 deaths where 
MDMA is mentioned in post-mortem toxicology of 
overdose cases in 2014, which is twice the number 
reported in 2013. This increase occurred in the context of a 
large increase in the overall number of drug-related deaths. 
It is important that this phenomenon is more thoroughly 
investigated before conclusions are drawn.
FIGURE 5
Clinical features related to acute MDMA toxicity (Euro-DEN data, 2014)
Source: Euro-DEN data, 2014.
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In England and Wales reports of MDMA-related deaths have 
also increased, although at lower levels. Similar to the 
situation in Turkey, this also occurred in the context of an 
overall increase in other drug-related deaths, but alongside 
a recent reduction in PMA/PMMA-related deaths (Figure 6). 
This distinction between trends in MDMA and PMMA is 
important, and in many countries a proportion of deaths 
that were attributed to MDMA were in fact associated with 
tablets adulterated with other substances, in particular 
with PMMA.
There is likely to be an underestimation of MDMA-related 
deaths, as is the case for drug-related deaths in general. 
There are limitations and variability across Europe in the 
identification and definition of drug-related deaths, and not 
all deaths are subject to autopsies and full toxicological 
screening. Post-mortem toxicology data are not always 
available, nor consistently used for coding and for the 
monitoring of drug-related deaths. This could be the case 
in particular in some of the countries with potential MDMA 
concerns.
I Discussion
I MDMA market recovery and consolidation 
Europe has experienced a recent resurgence in the use of 
MDMA, with much stronger tablets and powders now 
commonly available in several Member States. It appears 
that the resurgence of the drug began in 2010/2011, 
associated with the development of an alternative, 
synthetic pre-precursor that proved to be more reliably 
available than safrole or PMK. This underlines the 
importance of pre-precursors and understanding chemical 
processes, as they shape the market to some extent. It is 
possible that 2014 represented a peak year for high-purity 
pills (in countries such as the Netherlands and the United 
Kingdom), and there are reports that use of MDMA is 
becoming normalised in certain youth populations. This 
raises questions as to whether use of the drug has reached 
saturation point in some countries or whether there is the 
potential for it to spread further. 
However, the picture is not uniform across Europe. While 
overall it appears that Europe’s MDMA market is now in a 
period of consolidation, there may be some temporal ripple 
effects as late-comer countries catch up. Higher dose 
MDMA tablets currently appear to be available in many EU 
countries, although patterns of use are influenced by local 
stimulant markets; for example, patterns of MDMA use in 
the Czech Republic are influenced by methamphetamine 
trends, and the Spanish situation is interlinked with 
cocaine use. 
There also appears to be some limited interplay between 
MDMA and local NPS markets. One example is the 
potential interplay between cathinones such as 
mephedrone and MDMA, although the available evidence 
appears to suggest that NPS are generally added to other 
drugs rather than replacing them, particularly in 
established users (Moore et al., 2013). Also, MDMA and 
ecstasy tablets have been associated with both 
substitution and by-products (PMMA). Nonetheless, the 
situation where NPS rather than MDMA were the normal 
active ingredient in ecstasy tablets has largely been 
FIGURE 6
Number of MDMA- and PMA/PMMA-related deaths, 
2010–14 trend, England and Wales
Source: Office for National Statistics (ONS), 2015.
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Since 2000 the United States Drug Enforcement 
Administration and Food and Drug Administration 
have allowed research trials for studies on MDMA-
assisted psychotherapy for (treatment-resistant) 
post-traumatic stress disorder. Research trials are 
currently mainly carried out in Canada and the United 
States and have reached phase II stages with initial 
positive clinical responses – in this phase the drug is 
given to a larger group of people to see if it is 
effective and to further evaluate its safety. Phase III 
studies are scheduled for 2017.
Re-emergence of research on MDMA-
assisted therapy for mental disorders
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reversed since 2011, with MDMA re-occupying a central 
place in the drug market as a distinct commodity in itself.
I  Decentralised, more sophisticated and innovative models for production and supply
Market indicators suggest a complex MDMA market 
structure in which suppliers are innovating to encourage 
growth and adopting marketing strategies to gain a larger 
share of a growing market. The Netherlands and Belgium 
remain the global centre of MDMA production, but it is not 
clear that they will remain so indefinitely. OCGs in these 
countries appear to have maintained a competitive 
advantage so far with the specialisation of production and 
decentralisation of specific roles (expertise, logistics, 
specialisms, chemical recovery). Innovation and increased 
variation is evident in production processes (in terms of 
the precursors used, essential chemicals routes, 
equipment, production to order, internet sale and the use 
of postal services) and a growing range of products 
(MDMA oil, crystals, designer pills, logos, etc.). There is also 
innovation and decentralisation at the geographical level, 
potentially adding tiers of security and making the market 
more resilient to intervention. This includes both mobile 
production and dispersal of different stages of production. 
In addition, there is evidence of the use of third countries 
for importing precursors, and the emergence of new global 
markets (Turkey, Brazil, Australia, etc.) where EU countries 
are clearly exporters. 
In particular, the sale of MDMA via darknet markets on the 
deep web could potentially be a game changer, with new 
players entering the marketplace and the declining 
importance of established organisational structures, 
including OCGs.
I Consumer dynamics 
This study also raises the question of the role played by 
supply factors in shaping demand and driving new MDMA 
consumption behaviours. There are delays in the provision 
of available indicator data on patterns of MDMA use, in 
particular with general population surveys. Internet 
surveys are promising but have sampling weaknesses. 
Nevertheless, all the signs suggest an upturn in the use of 
MDMA in many European countries between 2011 and 
2015. 
Overall patterns of drug use are now probably more 
dynamic and complex than in the first iteration of MDMA 
use in the 1990s. A generational shift is evident among 
MDMA consumers, reflected in consumption patterns and 
differentiated product types and names. In some countries 
use is increasingly normative, with MDMA functioning as a 
consumer product within the recreational economy and 
less linked to specific subcultures and settings than in the 
past. This in turn raises new concerns around normalising 
higher dose MDMA products. In addition, the use of the 
internet, both for supply purposes and for consumer 
communication around product availability and quality, is 
becoming increasingly influential. Online forums are a 
nexus for discussions on product choice, which in turn is 
influenced by branding and product form. 
This new generation of MDMA users may challenge our 
existing approaches to working with consumers and 
require a rethink of our traditional nightlife interventions. 
I Harms: implications and questions
Although there are limited data on the prevalence of 
drug-related acute toxicity in Europe, overall the current 
level of serious acute harms associated with the use of 
MDMA appears to be low. However, there is concern related 
to high-dose MDMA tablets, adulteration with highly toxic 
substances such as PMMA and younger and uninformed 
users. At present, the reporting of hospital emergency 
presentations and drug-related deaths remains fairly 
rudimentary in many countries. There is also continued 
uncertainly around the harms related to chronic MDMA use, 
particularly the consumption of high doses over time. 
Interactions with other drug consumption patterns 
(especially sedatives, alcohol, tobacco and replacement 
stimulants) may become more important over time. 
Nevertheless, there is the potential for increases in MDMA-
related problems — there are a number of clear risk factors:
n  With increased rates of prevalence, the population at 
risk increases. 
n  With more novice users, the likelihood of problems 
linked to inexperience in drug taking increases. 
n  With increased doses of MDMA in available products, 
the relative risk of all users experiencing problems 
increases. 
The evident market instability in respect to potency is 
probably one of the greatest threats, with high variability of 
MDMA content in similar looking products. Although the 
increased market supply of MDMA potentially reduces the 
rationale for and likelihood of adulteration, the increased 
use of this drug at festivals and mainstream events 
continues to provide an opportunistic market for 
exploitation with ‘adulterants’. 
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The primary arena for harm reduction responses has been 
linked with product adulteration and higher dose MDMA 
products. Pill checking, issuing of warnings and alerts, and 
consumer information and advice have been implemented. 
This emerges as an area with an identified need for the 
development of new evidence for effectiveness and 
behavioural change. As the subcultural importance of 
MDMA has reduced — with use less tied into electronic 
dance music — the traditional harm reduction methods 
appear to be increasingly out of date, and an important 
finding of this study has been the need for services to 
engage and work with a new, younger generation of more 
mainstream users. 
There is clearly a central role for the Internet in expanding 
consumer reach and targeting differential consumer risk 
behaviours. This is likely to require the development of a 
consensus on and processes for effective messaging, and 
also the development of new intervention models across 
the areas of rapid response, harm reduction and 
prevention. 
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The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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